Background. Little data exist about the clinical management and survival of elderly patients with endometrial cancer. This study aimed to evaluate the management of elderly and very elderly patients with endometrial cancer as well as the overall survival (OS) rate, disease-free survival (DFS) rate, and cancer-specific survival (CSS) rate in a multicenter cohort. Methods. Data from 1228 patients with endometrial cancer who received primary treatment between January 2001 and December 2012 were collected from a multicenter database. Clinical management, DFS, CSS, and OS were analyzed. Results. Based on the international endometrial cancer risk classification, 36% (212/582) of women age 65 years or younger, 42% (220/526) of women ages 65-80 years, and 48% (58/120) of women older than 80 years showed highrisk endometrial cancer (p \ 0.001). Pelvic lymphadenectomy was performed for 85% (230/271) of the women age 65 years or younger and 46% (33/71) of the women older than 80 years (p \ 0.001). Radiotherapy was performed for 27% (33/120) of the very elderly and 40% (233/582) of the young patients (p = 0.009). The 3-year CSS rates were 95% (95% confidence interval [CI], 93-97%) for the women age 65 years or younger, 90% (95% CI, 87-94%) for the women ages 65-80 years, and 82% (95% CI, 73-93%) for the women older than 80 years (p \ 0.001). Conclusions. The elderly and very elderly patients with endometrial cancer showed poorer prognosis than young patients. The significant lower CSS rate for the elderly patients could have be due to both the higher rate of highrisk endometrial cancer and undertreatment. Specific 
guidelines for the management of elderly and very elderly patients with endometrial cancer are needed to improve their prognosis.
As life expectancy continues to increase, the cohort of people older than 65 years accounts for almost two thirds of new cancer cases and three fourths of cancer-related deaths. [1] [2] [3] Despite this trend, elderly patients have historically been underrepresented in clinical trials. [4] [5] [6] [7] Endometrial cancer is the most common gynecologic malignancy in the Western world, and in parallel with aging demographics, the incidence of endometrial cancer has been increasing. The average age at diagnosis is approximately 68 years [8] [9] [10] . According to estimates, in the United States, more than 54,870 cases are diagnosed each year, and 10,170 deaths related to this malignancy occurred in 2015. 11 The standard of care for endometrial cancer remains controversial, but it mainly includes comprehensive surgical staging as recommended by the International Federation of Gynecology and Obstetrics (FIGO) . 12 This can involve complex procedures such as pelvic and paraaortic lymphadenectomy and omentectomy, especially for high-risk endometrial cancer, [12] [13] [14] [15] [16] [17] and the biologic aggressiveness of endometrial cancer increases with age. [17] [18] [19] The benefit of applying these complex procedures to elderly patients remains unclear. Indeed, sparse data exist about overall survival and specific cancer-related death among elderly and very elderly patients.
In addition, available data are biased by the different definitions of ''older age'' and ''elderly'' used. 20 Some authors consider older age to be older than 65 years, whereas others use more strict parameters such as an age of 75-80 years. 21 This study aimed to evaluate the management of elderly and very elderly patients with endometrial cancer and their disease-free survival, overall survival, and cancer-specific survival rates in a large French multicenter cohort.
MATERIALS AND METHODS

Patients
Data on women with histologically proven endometrial cancer who received primary surgical treatment between January 2001 and December 2013 were abstracted from seven institutions in France with maintained endometrial cancer databases (Tours University Hospital, Tenon University Hospital, Dijon Cancer Centre, Rennes University Hospital, Lille University Hospital, Reims University Hospital, Creteil University Hospital, and Jean Verdier University Hospital) and from the Senti-Endo trial. 22 The research protocol was approved by the Institutional Review Board of the College National des Gynécologues et Obsté-triciens Français (CEROG 2014-GYN-020).
All the enrolled women underwent preoperative abdominopelvic magnetic resonance imaging (MRI) unless it was contraindicated, in which case a computed tomography (CT) scan was performed. The following clinical, surgical, and pathologic data were collected: age; body mass index (BMI, calculated as weight in kilograms divided by the square of height in meters), surgical procedure, nodal staging, and adjuvant therapy.
The patients were divided into three cohorts: young women (age B 65 years or younger), elderly women (ages 65-80 years), and very elderly women (age [ 80 years).
Histology
Lymph nodes (LNs) were considered positive when macro-or micrometastases were present. Macrometastases were defined as a single focus of metastatic disease per LN measuring more than 2 mm. Micrometastases were defined as a single focus of metastatic disease per LN measuring 0.2-2 mm. 23 A tumor was considered to have lymphovascular space involvement (LVSI) when tumor emboli were found within a space clearly lined by endothelial cells on a hematoxylin and eosin (H&E)-stained section. 24 Type 1 tumors consisted of endometrioid adenocarcinomas and mixed tumors with a mucinous, villoglandular, or tubular component in addition to the endometrioid component. For these tumors, the histologic grade was defined by the percentage of the undifferentiated component: grade 1 (\5%), grade 2 (6-50%), and grade 3 ([50%). When nuclear atypia was present, the grade was increased by 1 point. 25 Type 2 tumors were those with at least one serous clear cell or a carcinosarcoma component.
All 
Treatment and Follow-up Assessment
According to INCa guidelines, pelvic and paraaortic lymph node surgical staging is required for HIR and high-risk groups, and pelvic lymph node surgical staging is required for intermediate-risk groups. Adjuvant therapy was administered on an individual basis at the discretion of a multidisciplinary committee, based on the INCa guidelines, and included vaginal brachytherapy (VBT) and/or external beam radiotherapy (EBRT) and/or chemotherapy (CT) and clinical follow-up assessment. 27 Chemotherapy performed involved four cycles of carboplatin and taxol. The clinical follow-up evaluation consisted of physical examinations and the use of imaging techniques according to the findings. Follow-up visits were conducted every 3 months for the first 2 years, every 6 months for the following 3 years, and once a year thereafter. Disease recurrence was diagnosed by biopsy or imaging.
Outcome Measures
The primary outcome measures were date of recurrence, date of death, and date of cancer-related death. The secondary outcome measures were surgical staging compliance with French national guidelines 25 and surgical route (minimally invasive surgery, laparotomy, and vaginal surgery).
Statistical Analysis
Descriptive parameters were expressed as the mean ± standard deviation and median (range) when indicated. Frequencies were presented as percentages. Chi square and Fisher's exact tests were used as appropriate for categorical or ordinal variables. For continuous variables, t tests were used to compare two variables, and one-way analysis of variance (ANOVA) was used for more than two variables. Overall survival (OS) time was calculated in months from the date of surgery to death (related or unrelated to cancer) or to the date of the last follow-up visit for surviving patients. Cancer-specific survival (CSS) was calculated as the time from the date of surgery to cancerrelated death, and disease-free survival (DFS) was (11) 83 (14) 37 (7) 17 (14) 0.002 1 190 (15) 80 (14) 89 (17) 20 (17) C2 537 (44) 239 (41) 243 (46) 55 (46) NC 364 (30) 179 (31) 157 (30) 28 (23) (40) 278 (48) 183 (35) 34 (28) NC 299 (25) 153 (26) 125 (24) 21 (18) Diabetes Yes 186 (15) 87 (15) 75 (14) 24 (20) (27) 35 (29) Intermediate risk 155 (13) 63 (11) 80 (15) 12 (10) High-intermediate risk 120 (10) 54 (9) 56 (11) 10 (8) calculated as the time from the surgery to cancer recurrence. Women who were alive and without recurrence were censored at the date of the last follow-up visit. The Kaplan-Meier method was used to estimate the survival distribution. Tick marks indicate censored data. The comparison test chosen for analysis of survival was the log-rank test. Effects were expressed as hazard ratios (HRs) with 95% confidence intervals (CIs) as appropriate. Cox proportional hazard models included established prognostic factors (pathologic type, adjuvant therapies, and nodal and LVSI status). A p value lower than 0.05 was considered statistically significant. Data were managed in an Excel database (Microsoft, Redmond, WA, USA) and analyzed using R 3.0.2 software, available online.
RESULTS
Characteristics of the Study Population
During the study period, 1228 women with endometrial cancer were documented as having received primary surgical treatment according to the following distribution of the three age groups: 582 women (47%) age 65 years or younger, 526 women (43%) ages 67-80 years, and 120 women (10%) older than 80 years.
The median age of the women was 66 years (range, 28-88 years), and their median BMI was 28 kg/m 2 (range, 14.0-52.7 kg/m 2 ). The demographic and clinicopathologic characteristics of the whole cohort by age group are reported in Table 1 . The rate of comorbidities, such as diabetes, high blood pressure, and previous breast cancer, was significantly higher in the older groups.
Tumor Characteristics
The tumor characteristics are reported in Table 2 . Notably, the elderly and very elderly women experienced more endometrial cancers, with biologic parameters indicating a poor prognosis. Indeed, 55% (58/106) of the very elderly patients had a positive LVSI status versus 29% (148/516) of the young patients (p \ 0.001). Similarly, 48% (58/120) of very elderly patients showed high-risk endometrial cancer versus 37% (212/582) of the young patients (p = 0.003).
Surgical Procedures and Adjuvant Treatment
The surgical procedures are described in Table 3 . The very elderly patients had less laparoscopic surgery (50%, 56/112) than the young patients (62%, 314/508) (p = 0.015). Additionally, 59% (71/120) of the very elderly women required pelvic ± para-aortic lymphadenectomy according to French guidelines, whereas this rate was 47% (271/582) for the young women (p = 0.011). However, pelvic ± .para-aortic lymphadenectomy was performed for 46% (33/71) of the very elderly patients and 85% (230/271) of the young patients (p \ 0.001).
The adjuvant treatments are reported in Table 3 . Radiotherapy was performed for 28% (33/120) of the very elderly patients and 40% (233/582) of the young patients (p = 0.008). Chemotherapy was performed for 4% (5/120) of the very elderly patients and 19% (113/582) of the young patients (p \ 0.001). Additionally, 50% (60/120) of the very elderly and 35% (230/582) of the young patients with endometrial cancer required radiotherapy according to French guidelines (p = 0.003), whereas radiotherapy was performed for 55% (33/60) of the very elderly women and 85% (201/230) of the young patients (p = 0.013). Among the very elderly women, 40% (48/120) required chemotherapy according to French guidelines versus 30% (172/582) of the young women with endometrial cancer (p = 0.044), whereas chemotherapy was performed for 10% (5/48) of the very elderly women and 56% (96/172) of the young patients (p \ 0.001).
Survival Results
The whole cohort had a mean follow-up period of 34.9 ± 30.2 months. In the whole population, recurrences were observed in 240 of the 1228 women (19.5%). The The survival curves are shown in Fig. 1 . The CSS rate was significantly lower for the elderly and the very elderly patients (p \ 0.001) (Fig. 1) . The 3-year DFS, CSS, and OS rates are shown in Supplementary Table 1 (univariate analysis) and Table 4 (multivariate analysis).
DISCUSSION
The current study highlights the occurrence of more aggressive endometrial cancer in elderly patients (age [ 65 years) and very elderly patients (age [ 80 years) than in younger patients. 27 Despite a more aggressive histology (higher rate of type 2 cancer or LVSI), the elderly and very elderly women had significantly less surgical staging (less lymphadenectomy) and less adjuvant radio-or chemotherapy, even when adjuvant treatment was (31) 180 (34) 44 (37) Vaginal approach 40 (3) 11 (2) 6 (1) 12 (10) NC 149 (12) 74 (13) 78 (15) 8 (7) 0.002
Sentinel lymph node
Yes 304 (25) 153 (26) 137 (26) 14 (12) No 626 (51) 279 (48) 273 (52) 74 (62) NC 298 (24) 150 (26) 116 (22) 32 (26) (22) 100 (17) 108 (21) 59 (49) \0.001
Para-aortic lymphadenectomy Yes 129 (11) 80 (14) 46 (9) required by guidelines according to tumor status. Data from the follow-up evaluation highlight the fact that CSS was significantly lower among the elderly and very elderly women than among their younger counterparts. Thus, this higher rate of cancer-related mortality could be due to the occurrence of more aggressive endometrial cancer in elderly women as well as under treatment. The 3-year OS rate was lower than the CSS rate, indicating that death was due to cancer as well as to causes other than cancer. Thus, the joint causes of death in the elderly indicate that standard treatments should be performed for some elderly patients but that the entire group of elderly patients would not benefit from this standard treatment because some of them die of causes other than cancer. Our study emphasizes the urgent need for specific guidelines for elderly and very elderly patients with endometrial cancer. Physicians must consider which surgical staging to perform for elderly and very elderly women, especially for lymph node dissection associated with hysterectomy. Although minimally invasive surgery is feasible for the elderly and has shown fewer complications than laparotomy, 33 major complications (grades 3 and 4 according to the Clavien-Dindo classification) 34 remain higher for patients older than 70 years. 17 The performance of lymph node dissection increases the surgery length and the rate of complications, particularly in the elderly 28, 29 Nevertheless, known lymph node status remains crucial to tailoring adjuvant treatment, especially in high-risk endometrial cancer, which occurs more frequently among the elderly. 30, 31 Sentinel lymph node biopsy could resolve the question of node status in endometrial cancer because it addresses lymph node involvement with less morbidity. 22, 32, 33 Unfortunately, our results showed that sentinel lymph node biopsy was used less often for the elderly and very elderly patients with endometrial cancer despite their poorer prognosis.
The choice of adjuvant treatment depends not only on the cancer prognosis but also on life expectancy, especially among elderly and very elderly patients. In the current study, as in others, we showed that elderly and very elderly women received significantly less adjuvant chemo-and radiotherapy than younger patients despite their higher rate of high-risk endometrial cancer. [34] [35] [36] The post operative radiation therapy in endometrial carcinoma (PORTEC)-1 trial showed that women older than 60 years were threefold more likely to have a locoregional recurrence after radical surgery than younger patients (HR, 3.90; p = 0.0017). 37 The local recurrence rate in the PORTEC-1 study population was reduced from 15.5 to 6% with the addition of postoperative external beam radiotherapy (EBRT). Notably, in the current study, the elderly had significantly less EBRT, although late radiation toxicity did not differ significantly between patients age 64 years or younger, 65-74 years, and 75 years or older. 38 One limitation of the current study was its retrospective nature, which led to missing data. However, the current cohort was very large, one of the most important published to date, 19 and the patients were managed in tertiary centers, which used well-documented electronic charts.
Second, the median follow-up period for recurrence was relatively short. However, the majority of recurrences (74%, 63/85) occurred during the 2 years of follow-up evaluation. In addition, our median follow-up period was consistent with previous studies evaluating the prognosis of endometrial cancer. 39, 40 Third, during the data collection period, there were changes in staging methods (FIGO classification) 26 and in the indications for nodal staging and adjuvant therapies. For example, para-aortic lymph node dissection was not systematically recommended in France for high-risk patients before 2010. Likewise, in a recent pooled analysis of the PORTEC-1 and -2 trials on the clinical impact of LVSI, the authors reported that substantial LVSI remains the strongest independent prognostic factor for pelvic regional recurrence, distant metastasis, and OS. 15, 16 Hence, for unstaged women, EBRT is recommended by ESMO/ ESGO/ESTRO for unequivocally positive LVSI to reduce pelvic recurrence. 41 In the same way, chemotherapy currently is recommended for high-risk endometrial cancer. We noted less adjuvant treatment for the elderly and very elderly, but the younger counterpart did not always have optimal treatment, especially for high-risk endometrial cancer, because of these recommendation changes.
Besides, during the data collection period, perception of aging changed in the oncology field. The concept of frailty was introduced to assess therapeutic morbidity risk. 42, 44 The lower rate of lymph node dissection for the elderly and very elderly patients could have been due to a discrepancy between pre-and postoperative risk groups for whom lymph node dissection was not systematically recommended, mainly due to the associated morbidities. 45 Finally, no attempt was made to replace numeric age by criteria evaluating life expectancy. Defining elderly patients based on functional status using geriatric evaluation tools might have been more discriminatory than age alone. 46 Some validated tools exist to predict frailty 47 and toxicity from chemotherapy, 43, 44, 47 but not for oncologic surgery, and chronologic age remains a crucial determinant of treatment decisions. 48, 49 CONCLUSION Our large cohort study highlights the worse prognosis of endometrial cancer for elderly and very elderly patients than for their younger counterparts. Despite the significantly higher rate of high-risk endometrial cancer among the elderly, the rates of lymph node dissection and adjuvant therapy were significantly lower. The significantly lower CSS rate for these elderly populations could have been due not only to their higher rate of high-risk endometrial cancer but also to undertreatment.
